ClinicalTrials.gg
CompletedNCT07302945Updated Dec 26, 2025

A Single-volunteer Study of Immune Response Following OTS-412 Vaccinia Virus Systemic Injection(Self-experiment)

An Early Phase 1 interventional study of OTS-412 in Healthy Volunteer, sponsored by Bionoxx Inc.. Completed at 1 site in South Korea. Open to male participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-26.

Sponsored by Bionoxx Inc. · Early Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 3 years 10 months after the study started (first participant enrolled Jan 2022, registered Nov 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
1
Allocation
Not applicable
Sex
Male
01

Study summary

Following oncolytic virus (OV) administration, the host immune response is initiated immediately and evolves dynamically. However, in clinical OV therapy, it is virtually impossible to capture these immune events in real time. To address this gap, the principal investigator conducted a high-resolution immune monitoring study in a healthy volunteer.

02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

Bionoxx Inc. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A healthy adult

Exclusion criteria

Exclusion Criteria:

  • N/A
05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    OV Treated healthy arm

    Biological: OTS-412

Interventions

  • BiologicalOTS-412

    After hospitalization, OTS-412 was infused for one hour.

06

What researchers measure

Primary outcomes

  1. Changes in ANC(absolute neutrophil count) over time

    Time frame: 4 hour, 8 hour, 20 hour, 24 hour, Day 2, Day 5, Day 8, Day 16

  2. Changes in lymphocytes count over time

    Time frame: 4 hour, 8 hour, 20 hour, 24 hour, Day 2, Day 5, Day 8, Day 16

Secondary outcomes

  1. FLow cytometry

    CD surface subtyping for each sampling

    Time frame: 4 hour, 8 hour, 20 hour, 24 hour, Day 2, Day 5, Day 8, Day 16

Other outcomes

  1. Measurement of GFP expressing neutrophils following ex vivo infection with gfp report viral vector combined with CD surface phenotypes.

    Time frame: 4 hour, 48 hour, Day 8, Day 16

07

Study locations

1 site
  • Pusan National University Medical college
    Busan, 50612, South Korea
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2022 to primary completion in Jan 2022, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2025
First posted
Dec 24, 2025
StartActual
Jan 4, 2022
Primary completionActual
Jan 14, 2022
CompletionActual
May 2, 2022
Last update
Dec 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07302945
Lead sponsor
Bionoxx Inc.
Responsible party
Sponsor
First posted
Dec 24, 2025
Start date
Jan 4, 2022
Primary completion
Jan 14, 2022
Completion
May 2, 2022
Last update
Dec 26, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: OTS-412

Start the discussion